Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/cncy.22760 | DOI Listing |
Int J Surg
October 2024
Department of Pharmacy, College of Medicine and Health Sciences, Ambo University, Ambo, Ethiopia.
Cervical cancer ranks as the fourth most common cancer among women globally, posing a significant mortality risk. Persistent infection with high-risk human papillomavirus (HPV) is the primary instigator of cervical cancer development, often alongside co-infection with other viruses, precipitating various malignancies. This study aimed to explore recent biotechnological advances in understanding HPV infection dynamics, host interactions, and its role in oncogenesis.
View Article and Find Full Text PDFArch Dermatol Res
January 2025
Hautpartner Lübeck, Lindenplatz 6, 23554, Lübeck, Germany.
Plantar warts, or verrucae plantares, are skin lesions on the soles of the feet caused by human papillomavirus (HPV). These warts are prevalent and affect up to 33% of children and 3.5% of adults.
View Article and Find Full Text PDFObstet Gynecol Sci
January 2025
Nutrition and Clinical Services Division, International Centre for Diarrheal Disease Research, Dhaka, Bangladesh.
Human papillomavirus (HPV) is a key factor in gynecological oncology. This narrative review investigates the complex connection between HPV and various gynecological cancers. For a comprehensive exploration, we examined the association between persistent HPV infection and cervical cancer and its global prevalence.
View Article and Find Full Text PDFAIDS Res Hum Retroviruses
January 2025
Servicio de Ginecología y Obstetricia, Hospital Universitario Torrecárdenas, GAEPI-VPH (Grupo Andaluz para el Estudio y la Prevención de la Infección por VPH), Almería, Spain.
Infection with Human immunodeficiency virus (HIV) shows a higher risk of infection by Human papillomavirus (HPV). We aim to provide evidence about the effect of a -based vaginal gel (Papilocare®) for treating HPV in women with HIV. Women ≥25 years coinfected by endocervical HPV and with low-grade abnormal cervicovaginal cytology were treated for 6 months with Papilocare® in this observational, prospective, non-controlled pilot study.
View Article and Find Full Text PDFJ Immunother Cancer
January 2025
Department of gynecological oncology, Oslo University Hospital, Oslo, Norway
Background: Second-line treatment options for persistent, recurrent or metastatic (r/m) cervical cancer are limited. We investigated the safety, efficacy, and immunogenicity of the therapeutic DNA-based vaccine VB10.16 combined with the immune checkpoint inhibitor atezolizumab in patients with human papillomavirus (HPV)16-positive r/m cervical cancer.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!